化膿性汗腺炎（HS）：全球市場展望、流行病學、競爭格局和市場預測報告（32個主要市場），2025-2035年

市場概覽

• 法國HS市場預計將從2025年的2.05億美元成長到2035年的6.2億美元。
• 以下因素正在推動市場成長：
• 針對主要發炎路徑生物製藥的廣泛應用
• 提高對疾病的認知，提高對中度至重度化膿性汗腺炎病例的診斷準確率。
• 未來的成長取決於能否成功開發出能夠持續控制疾病並改善患者長期療效的新型標靶治療。

化膿性汗腺炎（HS）概述

化膿性汗腺炎（HS）是一種慢性全身性發炎性毛囊疾病，其特徵是反覆疼痛的深部結節、膿瘍、化膿性瘻管和進行性疤痕形成。雖然病灶多見於皮膚上易磨損且富含頂泌汗腺的區域，但其主要病理生理機制涉及毛囊頂端漏斗部角化過度和阻塞，隨後發生毛囊破裂、免疫調節和繼發性微生物增殖。診斷主要依賴臨床表現，治療策略則根據Hurley分期系統制定，並需監測代謝合併症。到2026年，治療策略正迅速從急性期的生活方式介入和經驗性抗生素抑制療法轉向針對中重度疾病的特異性生物療法。雖然 TNF-α 抑制劑仍是一種基本治療方法，但先進的白細胞介素-17A 和白細胞介素-17A/F 抑制劑已在分子水平上廣泛應用，以實現持續的皮膚清除和抑制炎症隧道形成，並且通常與廣泛的手術切除或去頂術相結合，用於解剖學上固定的纖維化病變。

主要亮點

• 在法國，預計到 2025 年，膿皰瘡 (HS) 的診斷病例數將增加到 2035 年的 178,286 例。
• 化膿性汗腺炎是一種慢性復發性發炎性皮膚病，其特徵是疼痛性病灶、膿瘍形成和進行性疤痕形成。
• 這種疾病帶給患者巨大的生理和心理負擔，嚴重影響他們的生活品質。
• 診斷延誤和長期治療選擇有限，導致疾病活動持續存在，患者需求無法滿足。

市場定義：

• 北美洲（美國、加拿大）
• 歐洲（奧地利、比利時、捷克、丹麥、芬蘭、法國、德國、希臘、義大利、荷蘭、挪威、波蘭、葡萄牙、俄羅斯、西班牙、瑞典、瑞士、英國）
• 中東（沙烏地阿拉伯、阿拉伯聯合大公國、科威特、土耳其）
• 亞太地區（澳洲、中國、香港、印度、印尼、日本、馬來西亞、紐西蘭、菲律賓、新加坡、韓國、台灣、泰國、越南）
• 非洲（埃及、奈及利亞、南非、摩洛哥）
• 南美洲/拉丁美洲（阿根廷、巴西、智利、哥倫比亞、墨西哥、秘魯）

格式化和更新訊息

• 詳細報告（PDF）
• 市場預測模型（基於微軟Excel）
• 流行病學數據（MS Excel，互動式工具）
• 高階主管洞察（PPT簡報）
• 其他功能：定期更新、自訂和顧問支援。
• 根據 Thelansis 的政策，我們確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

• 如何最佳化在 32 個市場（北美、歐洲、中東、亞太、非洲和南美/拉丁美洲）的藥物開發和生命週期管理策略？
• 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
• 未來十年市場收入和病患佔有率的預測是多少？
• 哪些因素對市場趨勢影響最大？
• 受訪專家對目前和新興的治療方法有何看法？
• 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
• 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
• 為確保藥物獲得批准並順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

• 北美洲（美國、加拿大）
• 歐洲（奧地利、比利時、捷克、丹麥、芬蘭、法國、德國、希臘、義大利、荷蘭、挪威、波蘭、葡萄牙、俄羅斯、西班牙、瑞典、瑞士、英國）
• 中東（沙烏地阿拉伯、阿拉伯聯合大公國、科威特、土耳其）
• 亞太地區（澳洲、中國、香港、印度、印尼、日本、馬來西亞、紐西蘭、菲律賓、新加坡、韓國、台灣、泰國、越南）
• 非洲（埃及、奈及利亞、南非、摩洛哥）
• 南美洲/拉丁美洲（阿根廷、巴西、智利、哥倫比亞、墨西哥、秘魯）

大公司

• Avalo Therapeutics, Inc.
• ACELYRIN Inc.
• Incyte Corporation
• Novartis Pharmaceuticals
• UCB Biopharma SRL
• Aclaris Therapeutics, Inc.
• Takeda
• Sanofi
• Merck Sharp &Dohme LLC
• Sonoma Biotherapeutics, Inc.
• Almirall, SA
• Shanghai Huaota Biopharmaceutical Co., Ltd.
• Eli Lilly and Company
• AbbVie
• Insmed Incorporated
• Pfizer
• Boehringer Ingelheim
• MoonLake Immunotherapeutics AG
• Vanda Pharmaceuticals
• Janssen Research &Development, LLC
• Bluefin Biomedicine, Inc.
• Navigator Medicines, Inc.
• Sinocelltech Ltd.
• Leadingtac Pharmaceutical（Shaoxing）Co., Ltd.
• Zura Bio Inc.

目錄

第1章：主要調查結果及分析師說明

• 主要趨勢：市場概況、SWOT分析、商業利益與風險等。

第2章：疾病背景

• 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章：流行病學

• 重點
• 發病率/盛行率
• 已確診並正在接受藥物治療的患者族群。
• 合併症
• 其他相關患者群

第4章 市場規模及預測

• 重點
• 市場促進因素與限制因素
• 按藥物類別分類的趨勢
• 各國具體趨勢

第5章 競爭情勢

• 目前的治療方法
• 重點
• 診斷和治療過程/演算法
• 目前主要療法－概述及關鍵意見領袖見解
• 新興療法
• 重點
• 值得關注的後期新興療法—概述、市場上市預期和關鍵意見領袖見解
• 值得關注的早期研發管線

第6章：未滿足的需求與TPP分析

• 尚未滿足的主要需求及其透過新興療法實現的潛力。
• TPP分析與KOL展望

第7章 監理與報銷環境

第8章附錄

Global Hidradenitis Suppurativa (HS) Market Outlook

Thelansis's "Global Hidradenitis Suppurativa (HS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) - 2025 To 2035" covers disease overview, epidemiology, kidney biopsy cases, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Hidradenitis Suppurativa treatment modalities options for the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America).

Hidradenitis Suppurativa (HS) Overview

Hidradenitis suppurativa is a chronic, systemic inflammatory follicular disorder characterized by recurrent, painful deep-seated nodules, abscesses, draining sinus tracts, and progressive scarring. Although lesions manifest anatomically in intertriginous zones rich in apocrine glands, the primary pathobiology is rooted in hyperkeratosis and occlusion of the terminal hair follicle infundibulum followed by follicular rupture, immune dysregulation, and secondary microbial propagation. Diagnosis is clinical, utilizing the Hurley staging system to direct intervention and tracking metabolic comorbidities. Management in 2026 transitions rapidly from acute lifestyle and empiric antibiotic suppression to target-specific biological therapies for moderate-to-severe disease. While TNF-alpha inhibition remains foundational, molecular strategies widely utilize advanced interleukin-17A and interleukin-17A/F inhibitors to achieve sustained skin clearance and reduce inflammatory tunnel formation, complemented by wide surgical excision or deroofing procedures for anatomically fixed fibrotic disease structures.

Key Highlights

• In France, diagnosed Hidradenitis Suppurativa (HS) cases are projected to increase from 138,486 in 2025 to 178,286 by 2035.
• HS is a chronic, recurrent inflammatory skin disease associated with painful lesions, abscess formation, and progressive scarring.
• The disease imposes a substantial physical and psychosocial burden, significantly affecting patients' quality of life.
• Delayed diagnosis and limited long-term treatment options continue to contribute to persistent disease activity and unmet patient needs.

Market Overview

• The France HS market is projected to grow from $205M in 2025 to $620M by 2035.
• Market growth is driven by:
• Increasing adoption of biologic therapies targeting key inflammatory pathways
• Growing disease awareness and improved diagnosis of moderate-to-severe HS cases
• Future growth will depend on the successful development of novel targeted therapies capable of achieving sustained disease control and improving long-term patient outcomes.

Market Definition:

• North America (United States, Canada)
• Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
• Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
• Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
• Africa (Egypt, Nigeria, South Africa, Morocco)
• South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• North America (United States, Canada)
• Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
• Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
• Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
• Africa (Egypt, Nigeria, South Africa, Morocco)
• South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Companies Mentioned

• Avalo Therapeutics, Inc.
• ACELYRIN Inc.
• Incyte Corporation
• Novartis Pharmaceuticals
• UCB Biopharma SRL
• Aclaris Therapeutics, Inc.
• Takeda
• Sanofi
• Merck Sharp & Dohme LLC
• Sonoma Biotherapeutics, Inc.
• Almirall, S.A.
• Shanghai Huaota Biopharmaceutical Co., Ltd.
• Eli Lilly and Company
• AbbVie
• Insmed Incorporated
• Pfizer
• Boehringer Ingelheim
• MoonLake Immunotherapeutics AG
• Vanda Pharmaceuticals
• Janssen Research & Development, LLC
• Bluefin Biomedicine, Inc.
• Navigator Medicines, Inc.
• Sinocelltech Ltd.
• Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.
• Zura Bio Inc.

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)